# The Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.

> **NCT06597526** · — · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Peritoneal Metastasis
- Gastric Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06597526
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-15
- **Primary completion:** 2028-03-31
- **Final completion:** 2029-05-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06597526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06597526, "The Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06597526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*